WO1999050281A2 - Collagen peptides and uses thereof - Google Patents
Collagen peptides and uses thereof Download PDFInfo
- Publication number
- WO1999050281A2 WO1999050281A2 PCT/GB1999/000992 GB9900992W WO9950281A2 WO 1999050281 A2 WO1999050281 A2 WO 1999050281A2 GB 9900992 W GB9900992 W GB 9900992W WO 9950281 A2 WO9950281 A2 WO 9950281A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- peptides
- collagen
- receptor
- amino acid
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 335
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 163
- 229920001436 collagen Polymers 0.000 title claims abstract description 101
- 102000008186 Collagen Human genes 0.000 title claims abstract description 99
- 108010035532 Collagen Proteins 0.000 title claims abstract description 99
- 102000005962 receptors Human genes 0.000 claims abstract description 46
- 108020003175 receptors Proteins 0.000 claims abstract description 46
- 239000012634 fragment Substances 0.000 claims abstract description 38
- 239000000126 substance Substances 0.000 claims abstract description 31
- 238000000034 method Methods 0.000 claims description 49
- 102000006495 integrins Human genes 0.000 claims description 41
- 108010044426 integrins Proteins 0.000 claims description 41
- 150000001413 amino acids Chemical class 0.000 claims description 37
- 230000003993 interaction Effects 0.000 claims description 30
- 150000007523 nucleic acids Chemical class 0.000 claims description 24
- 238000012360 testing method Methods 0.000 claims description 22
- 108020004707 nucleic acids Proteins 0.000 claims description 21
- 102000039446 nucleic acids Human genes 0.000 claims description 21
- 239000013638 trimer Substances 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 238000003556 assay Methods 0.000 claims description 14
- 230000014509 gene expression Effects 0.000 claims description 14
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 11
- 239000003112 inhibitor Substances 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 238000013461 design Methods 0.000 claims description 7
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 7
- 229960002591 hydroxyproline Drugs 0.000 claims description 7
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims description 7
- 125000000539 amino acid group Chemical group 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 230000004071 biological effect Effects 0.000 claims description 5
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- GVVPGTZRZFNKDS-JXMROGBWSA-N geranyl diphosphate Chemical group CC(C)=CCC\C(C)=C\CO[P@](O)(=O)OP(O)(O)=O GVVPGTZRZFNKDS-JXMROGBWSA-N 0.000 claims 2
- 230000000640 hydroxylating effect Effects 0.000 claims 2
- 230000002776 aggregation Effects 0.000 abstract description 5
- 238000004220 aggregation Methods 0.000 abstract description 5
- 230000004913 activation Effects 0.000 abstract description 4
- 230000003915 cell function Effects 0.000 abstract description 3
- 108010055795 Integrin alpha1beta1 Proteins 0.000 abstract 1
- 108010017642 Integrin alpha2beta1 Proteins 0.000 abstract 1
- 230000027455 binding Effects 0.000 description 52
- 210000004027 cell Anatomy 0.000 description 51
- 229940024606 amino acid Drugs 0.000 description 32
- 235000001014 amino acid Nutrition 0.000 description 31
- 229920001184 polypeptide Polymers 0.000 description 29
- 150000001875 compounds Chemical class 0.000 description 19
- 108010048623 Collagen Receptors Proteins 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 108010077026 collagen-related peptide Proteins 0.000 description 14
- 238000004132 cross linking Methods 0.000 description 13
- 102100025305 Integrin alpha-2 Human genes 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 102000012422 Collagen Type I Human genes 0.000 description 11
- 108010022452 Collagen Type I Proteins 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- 238000002844 melting Methods 0.000 description 9
- 230000008018 melting Effects 0.000 description 9
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 7
- 125000001151 peptidyl group Chemical group 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 102000009268 Collagen Receptors Human genes 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 239000007790 solid phase Substances 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 239000010432 diamond Substances 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 238000010647 peptide synthesis reaction Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 4
- 102000049320 CD36 Human genes 0.000 description 4
- 108010045374 CD36 Antigens Proteins 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- 102000001187 Collagen Type III Human genes 0.000 description 4
- 108010069502 Collagen Type III Proteins 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 4
- 101710176384 Peptide 1 Proteins 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 108010064773 platelet membrane glycoprotein VI Proteins 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 4
- 230000003019 stabilising effect Effects 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000005829 trimerization reaction Methods 0.000 description 4
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 3
- 102000005720 Glutathione transferase Human genes 0.000 description 3
- 108010070675 Glutathione transferase Proteins 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 102100037812 Medium-wave-sensitive opsin 1 Human genes 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 108010033276 Peptide Fragments Proteins 0.000 description 3
- 102000007079 Peptide Fragments Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108010077465 Tropocollagen Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- -1 mimetic Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000010118 platelet activation Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 241001515965 unidentified phage Species 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- KSDTXRUIZMTBNV-INIZCTEOSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)butanedioic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)O)C(O)=O)C3=CC=CC=C3C2=C1 KSDTXRUIZMTBNV-INIZCTEOSA-N 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- YDNMHDRXNOHCJH-UHFFFAOYSA-N 3-aminopyrrolidine-2,5-dione Chemical compound NC1CC(=O)NC1=O YDNMHDRXNOHCJH-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 101000777658 Homo sapiens Platelet glycoprotein 4 Proteins 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 102100031574 Platelet glycoprotein 4 Human genes 0.000 description 2
- 241000139306 Platt Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 239000007819 coupling partner Substances 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 150000002611 lead compounds Chemical class 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000010807 negative regulation of binding Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- 108010047303 von Willebrand Factor Proteins 0.000 description 2
- 102100036537 von Willebrand factor Human genes 0.000 description 2
- 229960001134 von willebrand factor Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
- GVIXTVCDNCXXSH-AWEZNQCLSA-N (2s)-2-amino-5-[[amino-[(2,2,4,6,7-pentamethyl-3h-1-benzofuran-5-yl)sulfonylamino]methylidene]amino]pentanoic acid Chemical compound OC(=O)[C@@H](N)CCCN=C(N)NS(=O)(=O)C1=C(C)C(C)=C2OC(C)(C)CC2=C1C GVIXTVCDNCXXSH-AWEZNQCLSA-N 0.000 description 1
- VVQIIIAZJXTLRE-QMMMGPOBSA-N (2s)-2-amino-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound CC(C)(C)OC(=O)NCCCC[C@H](N)C(O)=O VVQIIIAZJXTLRE-QMMMGPOBSA-N 0.000 description 1
- HZHXMUPSBUKRBW-FXQIFTODSA-N (4s)-4-[[2-[[(2s)-2-amino-3-carboxypropanoyl]amino]acetyl]amino]-5-[[(1s)-1-carboxyethyl]amino]-5-oxopentanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O HZHXMUPSBUKRBW-FXQIFTODSA-N 0.000 description 1
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 1
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 229930183010 Amphotericin Natural products 0.000 description 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
- JHFNSBBHKSZXKB-VKHMYHEASA-N Asp-Gly Chemical group OC(=O)C[C@H](N)C(=O)NCC(O)=O JHFNSBBHKSZXKB-VKHMYHEASA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 101800001415 Bri23 peptide Proteins 0.000 description 1
- 101800000655 C-terminal peptide Proteins 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 description 1
- 102000004237 Decorin Human genes 0.000 description 1
- 108090000738 Decorin Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101001078133 Homo sapiens Integrin alpha-2 Proteins 0.000 description 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000000507 Integrin alpha2 Human genes 0.000 description 1
- 102100025304 Integrin beta-1 Human genes 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000577979 Peromyscus spicilegus Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000004079 Prolyl Hydroxylases Human genes 0.000 description 1
- 108010043005 Prolyl Hydroxylases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- LSTJLLHJASXKIV-UHFFFAOYSA-N amino hexanoate Chemical group CCCCCC(=O)ON LSTJLLHJASXKIV-UHFFFAOYSA-N 0.000 description 1
- 229940009444 amphotericin Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000003352 cell adhesion assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010205 computational analysis Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 108010089485 convulxin Proteins 0.000 description 1
- 208000002528 coronary thrombosis Diseases 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 230000006334 disulfide bridging Effects 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000005274 electronic transitions Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000002847 impedance measurement Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000000990 laser dye Substances 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000013152 negative regulation of cell migration Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 238000000711 polarimetry Methods 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000012306 spectroscopic technique Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000003160 two-hybrid assay Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
Definitions
- the present invention relates to peptides, in particular peptides based on collagen sequences, useful in modulating platelet and other cell function, including aggregation and activation.
- the invention also relates to methods of production of such peptides, their assembly into trimers, and methods of use .
- Collagen is the most abundant protein in the human body, where it serves a crucial role in connective tissue, imparting tensile strength to bone, cartilage, skin and tendon, for example.
- About 20 different collagens are known, the products of discrete genes. Some of these collagens are fibrous in nature, exemplified by type I and type III collagen. Both of these are present in the blood vessel wall .
- Fibrous collagens are comprised of three a chains assembled as a triple helix, the tropocollagen molecule or collagen monomer. Two gene products, the discrete ⁇ l(I) and c ⁇ 2 (I) chains form type I collagen, which has the structure [ ⁇ l (I) ] 2 [ ⁇ 2 (I) ] -_ .
- Type III collagen has the trimeric structure [ ⁇ l(III)] 3 . Higher order structure is necessary for fibre formation, where triple helices assemble further to form ordered fibres from arrays of tropocollagen molecules .
- the ability of collagen to form triple helices arises from (i) the lack of a bulky side chain in G, so that the single proton substituent takes up little space close to the axis of the helix, (ii) the strained proline ring structure present in P and O allowing particular bends to occur in the polypeptide backbone of collagen so that triple-helical structure can be adopted, and (iii) intra-chain hydrogen bonding involving the hydroxyl group of 0 adding to the stability of the helix.
- Gps glycoproteins
- Examples of direct interaction would be, in platelets, binding of collagen to the integrin ⁇ 2/3l, (also known as GpIa-IIa or VLA 2 or CD49b/CD29) or binding to the uncharacterised receptor, GpVI (Kehrel, 1995; Sixma et al , 1995, Sixma et al 1997; Moroi and Jung, 1997) .
- Examples of indirect interaction include the use of accessory molecules, e.g. von illebrand factor, to form a bridge or crosslink between a specific domain of the collagen molecule and GpIB.
- Cell -collagen interactions are necessary for processes including wound healing, tumour metastasis, angiogenesis and neovascularisation, also (of particular interest) the activation of platelets leading to platelet aggregation which is the acute cause of thrombosis.
- Collagen may also support cell migration, including of vascular smooth muscle cells from the media of the artery to the intima, contributing to the development of atheroma, thickening of the arterial wall in atheroma.
- cells are induced to migrate by chemoattractant stimuli such as growth factors, they need physical adhesion to an underlying substrate to allow them to move.
- the integrins may provide the mechanical support, therefore, for cell motility.
- the present invention is based in part on experimental work concerning triple-helicity as a pre-requisite for cell-collagen interaction.
- Collagen can be denatured (melted) by heating above a critical temperature, typically 40 * C or higher, and when suitable precautions are taken to avoid the re-adoption of triple-helical structure, many cells do not recognise this denatured collagen, more commonly known as gelatin. Unless denatured collagen is allowed to re-form tropocollagen molecules, and for these to re-assemble as fibres, it does not interact with the platelet surface to cause platelet activation.
- Collagen receptors may be of several types, although the molecular architecture of some of these is not fully defined.
- the platelet receptor GpVI for example, is identified by its molecular weight, (-65 kDa) , by auto-antibodies possessed by a very few patients identified to date in Japan (Sugiyama et al 1993) , by the capacity to bind a particular snake venom known as convulxin (Polgar et al . , 1997) and, now, by means of work using GpVI -deficient platelets, by the capacity to bind synthetic peptides of the invention, such as a GPO-based polymer known as "Collagen-Related Peptide" or "CRP" (Morton et al .
- GpVI is not known, nor is its membrane topology, but it is defined in Moroi and Jung, 1997.
- Another platelet collagen receptor, CD36 or GpIV is sequenced and has a single trans- membrane domain (Greenwalt et al . , 1992; Platt & Gordon, 1998).
- CD36-binding motifs in the collagens are not known.
- the integrin ⁇ lBl is a better-defined collagen receptor.
- ⁇ 2 and ⁇ l members of the integrin family each with a single trans-membrane domain
- o ⁇ 2 ⁇ l is known to bind to collagen via a specialised region of the Q!2-subunit, known as the I-domain, which bears sequence homology to the I-domain of von Willebrand factor.
- the integrins are widely-distributed in different cells, and cell- collagen interaction at large may often be mediated directly by ⁇ l integrins, either ⁇ 2 ⁇ l or ⁇ l ⁇ l (Hynes, 1992) .
- CB peptides are quite long, perhaps more than 100 amino acids, and can be renatured to form defined triple-helical fragments of the parent collagen molecules . They are known by their order of elution from the purification procedure, as for example ⁇ l(I)CB3 - the third CB peptide from the ⁇ l-chain of type I collagen. Some of these CB peptides, renatured and in triple-helical form, bind to platelets, whereas others do not. The use of monoclonal or other specific antibodies directed against particular receptors allows the identification of the platelet collagen receptors supporting this interaction.
- This sequence is not long enough, nor has it sufficient GPO content to adopt a triple-helical conformation spontaneously. To achieve this, it is synthesised with several GPOtriplets at either end of the sequence in question. GPP triplets will serve the same purpose.
- the C-terminus may be covalently linked using N-linked aminohexanoate residues coupled to a lysyl-lysyl group.
- the incorporation of a cysteine or other reactive residue at the N-terminus or C-terminus or both of each of the three component peptide chains allows subsequent crosslinking of the triple- helical structures (Morton et al . , 1995).
- ⁇ 2/3l recognition sequence embraced by these peptides identified as being contained by the collagen-derived sequence from the overlap region of peptides 5 and 6, re-synthesised as Table 1 peptide 5/6, was also synthesised within GPP N-terminal and C-terminal sequences, as an alternative means of stabilising the triple helix.
- This peptide lacking GPO sequences, does not react with GpVI and is thus specific for o ⁇ 2 ⁇ l .
- a peptide fragment of collagen consisting of the amino acid sequence GFOGERGVEGPOGPA (SEQ ID NO. 1) , or a fragment thereof which retains ability to interact with and/or bind the ⁇ ;2/3l receptor.
- the present invention also provides a peptide of the sequence GFPGERGVEGPPGPA (SEQ ID NO. 2) , that is the collagen fragment of the first aspect of the invention in which Proline (P) is substituted for Hydroxyproline (O) .
- GFPGERGVEGPPGPA SEQ ID NO. 2
- peptides which are sequence variants of these two peptides SEQ ID NO. 1 and SEQ ID NO. 2 , which are made that are successively shorter by a single amino acid or more, to locate the minimum sequence recognising a>2 ⁇ l .
- One such peptide has the active sequence, GFOGER, SEQ ID NO.3.
- peptides which are sequence variants of one of these peptides SEQ ID NO.l, SEQ ID NO. 2 and SEQ ID NO .3 , retaining ability to bind 0-2/31, and having at least 10/15 amino acid identity with SEQ ID NO. 1 or SEQ ID NO. 2, preferably at least 11/15 amino acid identity, more preferably 12/15, 13/15 or 14/15, or having at least 3/6 amino acid identity, or more preferably 4/6 or 5/6 amino acid identity with SEQ ID NO. 3.
- a peptide according to such an aspect retains each of the phenylalanine (F) , the glutamyl (E) , and the arginyl (R) residues within the GFOGER motif, assuming ability to bind ⁇ :2/3l is desired. Binding activity may be retained if the Hydroxyproline (O) is substituted with proline (P) , the E is substituted with Aspartate (D) , or the R is substituted with Lysine (K) and any other substitution which does not abolish binding activity may be made, the person skilled in the art easily being able to test this.
- O Hydroxyproline
- P proline
- D Aspartate
- K Lysine
- one or other of these critical residues may be replaced with another amino acid, such as A (as experimentally exemplified) , or residues such as His, Lys or Arg, particularly Tryp, Tyr or Phe .
- A amino acid
- residues such as His, Lys or Arg, particularly Tryp, Tyr or Phe .
- Such peptides serve as structurally- inactive analogues, useful for example in in vi tro adhesion studies .
- Non-naturally occurring peptides and polypeptides including such a collagen fragment are also provided as aspects of the present invention, particularly wherein the collagen fragment or variant thereof is fused to one or more non-collagen sequences.
- the invention also includes derivatives of the peptides, including the peptide linked to a coupling partner, e.g.
- an effector molecule such as an antibody or binding fragment thereof or other ligand.
- a label such as an antibody or binding fragment thereof or other ligand.
- Peptides according to various aspects of the present invention may be able to bind the o;2 I-domain of the ⁇ 2/3l integrin receptor separate or in isolation from the remainder of the integrin, or in the complete heteromer. Peptides may be assessed for ability to bind using complete o ⁇ 2 ⁇ l , the ⁇ 2 I- domain, or a fragment or variant thereof able to bind collagen and/or bind the GFOGERGVEGPOGPA motif or GFOGER of the invention.
- a peptide including GPP repeats and a collagen fragment, or variant or derivative thereof as discussed, preferably a collagen fragment or variant able (at least in a trimer) to interact with and/or bind the a2 ⁇ l collagen receptor.
- a peptide will form a trimer under appropriate conditions, but will not bind and/or stimulate the collagen receptor GpVI.
- the peptide is non-naturally occurring, i.e. it is one not found in nature.
- GPP repeats are included so as to flank said collagen fragment or variant, and may be at or adjacent to the termini of the peptide.
- the collagen fragment or variant able to interact with and/or bind the o>2 ⁇ l collagen receptor may include or consist of the GGPOGPR fragment (Morton et al . 1991 ) or a fragment or variant in accordance with other aspects of the invention as disclosed herein, including in the discussion above (e.g. GFOGERGVEGPOGPA or GFPGERGVEGPPGPA or GFOGER) .
- trimers of the peptide which are able to interact with the ⁇ ;2/3l collagen receptor but not the GpVI collagen receptor.
- peptides of the invention exemplified by the GFOGER motif of SEQ ID NO. 3, are also recognised by the ⁇ l integrin I- domain, they may be used interact with and modulate activity of integrin otl ⁇ l .
- the present invention provides a peptide including GPO repeats and a collagen fragment or variant or derivative thereof as disclosed, preferably a collagen fragment or variant able (at least in a trimer) to interact with and/or bind the o;2/3l collagen receptor.
- a peptide will form a trimer under appropriate conditions, and will bind and/or stimulate the collagen receptor GpVI.
- the peptide is non- naturally occurring, i.e. it is one not found in nature.
- GPO repeats are included so as to flank said collagen fragment or variant, and may be at or adjacent to the termini of the peptide.
- the collagen fragment or variant able to interact with and/or bind the c*2/3l collagen receptor may include or consist of the GGPOGPR (Morton et al . 1997) but is most preferably a fragment or variant in accordance with other aspects of the invention as disclosed herein, including in the discussion above .
- This provides for trimers of the peptide which are able to interact with the ot2 ⁇ l collagen receptor and are also able to interact with the GpVI collagen receptor.
- a molecule in accordance with the present invention may include GPP and/or GPO units. Furthermore, triple helical conformation may be supported by repetitive GPF motifs at each end of the specified sequence, where, in addition to the possibilities present by P and/or 0, any amino acid which preserves triple-helical stability, e.g. A or R, may be used.
- Peptides of the invention need not include any hexanoic acid cross-linking for trimerization (such as the lysyl-lysyl amino hexanoate cross-linking illustrated experimentally below) .
- a peptide in accordance with an aspect of the present invention may include one or more heterologous amino acids joined to the collagen fragment, in addition to the optional GPP or GPO repeats.
- heterologous is meant not occurring in the relevant collagen joined by a peptide bond without intervening amino acids to the relevant collagen fragment, that is to say usually a chain of amino acids which is not found naturally joined to the collagen fragment at the position of fusion in the peptide of the invention.
- the contiguous sequence of amino acids does not occur within collagen, and may be 5 or more, preferably 10 or more, more preferably 15 or more, 20 or more or 30 or more amino acids with a sequence which does not occur contiguously in collagen.
- Peptides according to different aspects of the present invention tend to be short, and may be about 60 amino acids in length or less, preferably about 50 amino acids in length or less, preferably about 40 amino acids in length or less, preferably about 35 amino acids in length or less, preferably about 30 amino acids in length, or less, preferably about 25 amino acids or less, preferably about 20 amino acids or less, preferably about 15 amino acids or less, preferably about 10 amino acids or less.
- Peptides may be 10-15, 15-20, 20-25, 25- 30, 30-35, 35-40, 40-50 or 50-60 amino acids in length.
- the number of triplet repeats may be about 3-5, possibly 2, preferably 3, 4 or 5. Greater than 5 may be included (perhaps less than about 10) , though may not be necessary since 3, 4 or 5 repeats are stable as a triple helix at room temperature.
- Peptides according to different aspects of the present invention may be homotrimeric as described above, where all three chains have identical sequence, but may also be heterotrimeric in nature, that is at least one of the chains is different from the others, and two but not three chains may be identical in sequence.
- one or two but not three chains may incorporate receptor-specific recognition motifs, such as SEQ ID NO. 3, GFOGER, specific for ⁇ 2/?l or ⁇ l ⁇ l, or GPO motifs specific for GpVI .
- receptor-specific recognition motifs such as SEQ ID NO. 3, GFOGER, specific for ⁇ 2/?l or ⁇ l ⁇ l, or GPO motifs specific for GpVI .
- covalent crosslinking preferably at the C- terminus, using suitable means. Procedures suitable for assembling heterotrimers are established in the art, e.g. M. Goodman et al , (1996) .
- a peptide according to the present invention may be provided as a fusion with a non-collagen peptide or polypeptide or polypeptide domain. Where it is desired to take advantage of the trimerizing properties of peptides of the invention, any fusion will need to be such as not to interfere with the trimerization.
- Multiple specificities may be presented in a single molecule, e.g. for crosslinking receptors to a2 ⁇ l and/or GpVI, allowing for examination of interactions between receptors and of intracellular events resulting from such heterogeneous interactions, also for such biological response to be harnessed in therapeutic and/or diagnostic contexts.
- the present invention provides for the incorporation of multiple copies of receptor-reactive sequences, to induce homogeneous crosslinking of the specified or other receptors.
- GFOGER spaced at suitable intervals, for example by intervening GPP triplets, up to 10 triplets, may be used for crosslinking of two copies of the receptor ⁇ 2/3l.
- sequences specific for other collagen receptors such as GPO which is specific for the receptor GpVI, may be used for crosslinking of GpVI.
- GPO which is specific for the receptor GpVI.
- the present invention provides peptide trimers including one or more peptides according to the present invention, preferably consisting of three peptides according to the invention.
- a still further aspect provides a method of making a peptide trimer, the method including providing peptides of the invention and causing or allowing (under appropriate conditions) the peptides to associate to form a trimer.
- Trimerization may be followed by isolation of trimers, e.g. for subsequent use and/or manipulation.
- peptides in accordance with the present invention may be cyclized. This reduces the degrees of freedom of a peptide substantially, so that it may interact with higher affinity with suitably-configured targets, such as receptors. Chemistry for achieving this is available in the art, e.g. on commercially available solid-phase peptide synthesizers. Peptides may be provided as cyclic dendrimers, species bearing the desired peptides as loops, typically of 5 or so at each end of a short spacer sequence (Shao and Tarn, 1995) .
- Peptides may be used in influencing cell adhesion to collagen and/or other cell types, particularly adhesion of platelets, smooth muscle cells, tumour cells or vascular endothelial cells. They may be used to affect activation of cells, such as platelets, modulating, particularly inhibiting or blocking, activation. This may be in a therapeutic context, e.g. to treat or prevent thrombosis.
- Peptides may be generated wholly or partly by chemical synthesis.
- the compounds of the present invention can be readily prepared according to well-established, standard liquid or, preferably, solid-phase peptide synthesis methods, general descriptions of which are broadly available (see, for example, in J.M. Stewart and J.D. Young, Solid Phase Peptide Synthesis, 2nd edition, Pierce Chemical Company, Rockford, Illinois (1984) , in M. Bodanzsky and A. Bodanzsky, The Practice of Peptide
- peptidyl molecule Another convenient way of producing a peptidyl molecule according to the present invention (peptide or polypeptide) is to express nucleic acid encoding it, by use of nucleic acid in an expression system. This is particularly applicable for peptides not including O, such as those including GPP repeats and no GPO repeats and those including or based on SEQ ID NO. 2, rather than SEQ ID NO. 1, although production of GPO-containing peptides may be achieved for example by co-expression of an appropriate hydroxylase, as has been done with lysyl residues
- prolyl -hydroxylase may be co-expressed.
- the present invention also provides in various aspects nucleic acid encoding the polypeptides and peptides of the invention.
- nucleic acid according to the present invention is provided as an isolate, in isolated and/or purified form, except possibly one or more regulatory sequence (s) for expression.
- Nucleic acid in accordance with the present invention may be provided as part of a recombinant vector.
- Nucleic acid sequences encoding a polypeptide or peptide in accordance with the present invention can be readily prepared by the skilled person using the information and references contained herein and techniques known in the art (for example, see Sambrook, Fritsch and Maniatis, "Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1989, and Ausubel et al , Current Protocols in Molecular Biology, John Wiley and Sons, 1992) .
- the sequences can be incorporated in a vector having one or more control sequences operably linked to the nucleic acid to control its expression.
- the vectors may include other sequences such as promoters or enhancers to drive the expression of the inserted nucleic acid, nucleic acid sequences so that the polypeptide or peptide is produced as a fusion and/or nucleic acid encoding secretion signals so that the polypeptide produced in the host cell is secreted from the cell.
- Polypeptide can then be obtained by transforming the vectors into host cells in which the vector is functional, culturing the host cells so that the polypeptide is produced and recovering the polypeptide from the host cells or the surrounding medium.
- Prokaryotic and eukaryotic cells are used for this purpose in the art, including strains of E. coli, yeast, and eukaryotic cells such as COS or CHO cells.
- the present invention also encompasses a method of making a polypeptide or peptide (as disclosed) , the method including expression from nucleic acid encoding the polypeptide or peptide (generally nucleic acid according to the invention) .
- This may conveniently be achieved by growing a host cell in culture, containing such a vector, under appropriate conditions which cause or allow expression of the polypeptide.
- Polypeptides and peptides may also be expressed in in vi tro systems, such as reticulocyte lysate.
- a further aspect of the present invention provides a host cell containing heterologous nucleic acid as disclosed herein.
- the nucleic acid of the invention may be integrated into the genome (e.g. chromosome) of the host cell. Integration may be promoted by inclusion of sequences which promote recombination with the genome, in accordance with standard techniques.
- the nucleic acid may be on an extra-chromosomal vector within the cell, or otherwise identifiably heterologous or foreign to the cell.
- a still further aspect provides a method which includes introducing the nucleic acid into a host cell.
- the introduction which may (particularly for in vi tro introduction) be generally referred to without limitation as "transformation” , may employ any available technique.
- suitable techniques may include calcium phosphate transfection, DEAE-Dextran, electroporation, liposome-mediated transfection and transduction using retrovirus or other virus, e.g. vaccinia or, for insect cells, baculovirus .
- suitable techniques may include calcium chloride transformation, electroporation and transfection using bacteriophage .
- direct injection of the nucleic acid could be employed.
- Marker genes such as antibiotic resistance or sensitivity genes may be used in identifying clones containing nucleic acid of interest, as is well known in the art.
- the introduction may be followed by causing or allowing expression from the nucleic acid, e.g. by culturing host cells (which may include cells actually transformed although more likely the cells will be descendants of the transformed cells) under conditions for expression of the gene, so that the encoded polypeptide (or peptide) is produced. If the polypeptide is expressed coupled to an appropriate signal leader peptide it may be secreted from the cell into the culture medium. Following production by expression, a polypeptide or peptide may be isolated and/or purified from the host cell and/or culture medium, as the case may be, and subsequently used as desired, e.g.
- a composition which may include one or more additional components, such as a pharmaceutical composition which includes one or more pharmaceutically acceptable excipients, vehicles or carriers (e.g. see below).
- Peptides and polypeptides in accordance with the present invention may be used in assays for molecules which affect interaction of collagen with c2/3l receptor and/or GpVI receptor, particularly molecules which are non-peptidyl mimetics of peptides such as those disclosed herein able to bind ⁇ 2/3l and/or GpVI.
- An assay method in accordance with the present invention may involve bringing into contact a peptide of the invention and either or both of the o ⁇ 2 ⁇ l and GpVI receptors, along with a test substance, under conditions wherein in the absence of the test substance being an inhibitor of interaction between the peptide and the receptor the peptide and receptor interact, and determining interaction.
- an assay may be designed in which the peptide and receptor are provided under conditions in which they do not interact unless a test substance is able to sufficiently enhance interaction.
- the precise format of an assay of the invention may be varied by those of skill in the art using routine skill and knowledge.
- Suitable detectable labels, especially for peptidyl substances include 35 S-methionine which may be incorporated into recombinantly produced peptides and polypeptides.
- Recombinantly produced peptides and polypeptides may also be expressed as a fusion protein containing an epitope which can be labelled with an antibody.
- the protein which is immobilized on a solid support may be immobilized using an antibody against that protein bound to a solid support or via other technologies which are known per se .
- a preferred in vi tro interaction may utilise a fusion protein including glutathione-S-transferase (GST) . This may be immobilized on glutathione agarose beads.
- GST glutathione-S-transferase
- a test compound can be assayed by determining its ability to diminish the amount of labelled peptide or polypeptide which binds to the immobilized GST-fusion polypeptide. This may be determined by fractionating the glutathione-agarose beads by SDS-polyacrylamide gel electrophoresis .
- the beads may be rinsed to remove unbound protein and the amount of protein which has bound can be determined by counting the amount of label present in, for example, a suitable scintillation counter.
- a two-hybrid assay may be designed in accordance with standard practice.
- Peptides and other molecules may be assessed for ability to bind 0L2 ⁇ l and/or GpVI collagen receptors, modulate, particularly inhibit or block, platelet activation, or cellular adhesion (e.g. of HT 1080 cells) , affect cell migration, for example of vascular smooth muscle cells, tumour cells or vascular endothelial cells or to regulate cell proliferation or cell survival.
- cellular adhesion e.g. of HT 1080 cells
- Assays may involve test substances which block the action of native collagen fibres, in aggregation or adhesion or other tests of cell function. Substances may be used or found which displace cells from an underlying native collagen substrate. Alternatively, peptides may form an adhesive substrate, with test substances being applied to test efficacy in displacing cells or receptors which bind, or in affecting one or more cellular processes such as cell migration, proliferation or survival .
- test substance or compound which may be added to an assay of the invention will normally be determined by trial and error depending upon the type of compound used. Typically, from about 0.01 nM to 100 ⁇ M or more concentrations of putative inhibitor compound may be used, for example from 0.1 to 50 ⁇ M, particularly 3nM to 30 ⁇ M, such as about 10 ⁇ M. Greater concentrations may be used when a peptide is the test substance . Even a molecule with weak binding may be a useful lead compound for further investigation and development.
- Compounds which may be used may be natural or synthetic chemical compounds used in drug screening programmes. Extracts of plants which contain several characterised or uncharacterised components may also be used. Antibodies directed to the site of interaction in either protein form a further class of putative inhibitor compounds. Candidate inhibitor antibodies may be characterised and their binding regions determined to provide single chain antibodies and fragments thereof which are responsible for disrupting the interaction.
- Antibodies may be obtained using techniques which are standard in the art .
- Performance of an assay method according to the present invention may be followed by isolation and/or manufacture and/or use of a compound, substance or molecule which tests positive.
- the substance or agent may be investigated further.
- it may be manufactured and/or used in preparation, i.e. manufacture or formulation, of a composition such as a medicament, pharmaceutical composition or drug. These may be administered to individuals, e.g. for any of the purposes discussed elsewhere herein.
- the agent may be peptidyl, e.g. a peptide which includes a sequence as recited above, or may be a functional analogue of such a peptide.
- the expression "functional analogue” relates to peptide variants or organic compounds having the same functional activity as the peptide in question, which may interfere with the binding between collagen and the relevant receptor.
- analogues include chemical compounds which are modelled to resemble the three dimensional structure of the relevant collagen fragment in the contact area, and in particular the arrangement of the key amino acid residues as they appear in collagen.
- the present invention provides the use of the above substances in methods of designing or screening for mimetics of the substances.
- the present invention provides a method of designing mimetics of a peptide or other molecule of the invention, said method including:
- modelling the pharmacophore to design and/or screen candidate mimetics having the biological activity Suitable modelling techniques are known in the art. This includes the design of so-called “mimetics” which involves the study of the functional interactions of fluorogenic derivatives of target receptors, e.g. oil ⁇ l , a.2 ⁇ l or GpVI, with their respective recognition motifs and the design of compounds which contain functional groups arranged in such a manner that they could reproduce those interactions.
- the designing of mimetics to a known pharmaceutically active compound is a known approach to the development of pharmaceuticals based on a "lead" compound. This might be desirable where the active compound is difficult or expensive to synthesise or where it is unsuitable for a particular method of administration, e.g. peptides may not be well suited as active agents for oral compositions as they tend to be quickly degraded by proteases in the alimentary canal. Mimetic design, synthesis and testing may be used to avoid randomly screening large number of molecules for a target property.
- the particular parts of the compound that are critical and/or important in determining the target property are determined.
- this can be done by systematically varying the amino acid residues in the peptide, e . g . by substituting each residue in turn.
- These parts or residues constituting the active region of the compound are known as its "pharmacophore" .
- the pharmacophore Once the pharmacophore has been found, its structure is modelled to according its physical properties, e.g. stereochemistry, bonding, size and/or charge, using data from a range of sources, e.g. spectroscopic techniques, X-ray diffraction data and NMR. Computational analysis, similarity mapping (which models the charge and/or volume of a pharmacophore, rather than the bonding between atoms) and other techniques can be used in this modelling process.
- a range of sources e.g. spectroscopic techniques, X-ray diffraction data and NMR.
- Computational analysis, similarity mapping which models the charge and/or volume of a pharmacophore, rather than the bonding between atoms
- other techniques can be used in this modelling process.
- the three-dimensional structure of the ligand and its binding partner are modelled. This can be especially useful where the ligand and/or binding partner change conformation on binding, allowing the model to take account of this the design of the mimetic.
- a template molecule is then selected onto which chemical groups which mimic the pharmacophore can be grafted.
- the template molecule and the chemical groups grafted on to it can conveniently be selected so that the mimetic is easy to synthesise, is likely to be pharmacologically acceptable, and does not degrade in vivo, while retaining the biological activity of the lead compound.
- the mimetic or mimetics found by this approach can then be screened to see whether they have the target property, or to what extent they exhibit it. Further optimisation or modification can then be carried out to arrive at one or more final mimetics for in vivo or clinical testing.
- the mimetic or mimetics found by this approach can then be screened to see whether they have the target property, or to what extent they exhibit it. Further optimisation or modification can then be carried out to arrive at one or more final mimetics for in vivo or clinical testing.
- the present invention further provides the use of a peptide which includes a sequence as disclosed, or a derivative, active portion, analogue, variant or mimetic, thereof able to interact with the c2/3l collagen receptor and/or the GpVI collagen receptor, in screening for a substance able to modulate interaction between collagen and such a receptor.
- such a substance e.g. peptide, mimetic, inhibitor, according to the present invention is provided in an isolated and/or purified form, i.e. substantially pure.
- This may include being in a composition where it represents at least about 90% active ingredient, more preferably at least about 95%, more preferably at least about 98%.
- Such a composition may, however, include inert carrier materials or other pharmaceutically and physiologicaly acceptable excipients.
- a composition according to the present invention may include in addition to an inhibitor compound as disclosed, one or more other molecules of therapeutic use.
- the present invention extends in various aspects not only to peptides and other substances identified as disclosed, but also a pharmaceutical composition, medicament, drug or other composition comprising such a substance, a method comprising administration of such a composition to a patient, e.g. for a purpose discussed elsewhere herein, which may include preventative treatment, use of such a substance in manufacture of a composition for administration, e.g. for a purpose discussed elsewhere herein, and a method of making a pharmaceutical composition comprising admixing such a substance with a pharmaceutically acceptable excipient, vehicle or carrier, and optionally other ingredients.
- a pharmaceutically useful compound according to the present invention that is to be given to an individual is preferably administered in a "prophylactically effective amount” or a “therapeutically effective amount” (as the case may be, although prophylaxis may be considered therapy) , this being sufficient to show benefit to the individual.
- a pharmaceutically useful compound according to the present invention is preferably administered in a "prophylactically effective amount” or a “therapeutically effective amount” (as the case may be, although prophylaxis may be considered therapy) , this being sufficient to show benefit to the individual.
- the actual amount administered, and rate and time-course of administration will depend on the nature and severity of what is being treated. Prescription of treatment, e.g. decisions on dosage etc, is within the responsibility of general practitioners and other medical doctors .
- a composition may be administered alone or in combination with other treatments, either simultaneously or sequentially dependent upon the condition to be treated.
- compositions according to the present invention may include, in addition to active ingredient, a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient.
- a pharmaceutically acceptable excipient such materials should be non-toxic and should not interfere with the efficacy of the active ingredient.
- the precise nature of the carrier or other material will depend on the route of administration, which may be oral, or by injection, e.g. cutaneous, subcutaneous or intravenous.
- compositions for oral administration may be in tablet, capsule, powder or liquid form.
- a tablet may include a solid carrier such as gelatin or an adjuvant.
- Liquid pharmaceutical compositions generally include a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol , propylene glycol or polyethylene glycol may be included.
- the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability.
- a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability.
- isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's Injection.
- Preservatives, stabilisers, buffers, antioxidants and/or other additives may be included, as required.
- Liposomes, particularly cationic liposomes may be used in carrier formulations.
- the agent may be administered in a localised manner to a desired site or may be delivered in a manner in which it targets particular cells or tissues.
- a composition may be administered alone or in combination with other treatments, either simultaneously or sequentially dependent upon the condition to be treated.
- a polypeptide, peptide or other substance as disclosed herein, or a nucleic acid molecule encoding a peptidyl such molecule may be provided in a kit, e.g. sealed in a suitable container which protects its contents from the external environment.
- a kit may include instructions for use.
- Peptides and other substances according to the present invention as disclosed herein may be directed by virtue of ⁇ 2/3l- and/or GpVI -recognition motifs towards particular cellular receptors for collagen.
- the following applications are provided as further aspects of the present invention:
- Peptides may be covalently labelled with an indicator such as a fluorescent dye, e.g. fluorescein or rhodamine, or a radiochemical label, e.g. 125 I, or biotin, allowing subsequent combination with labelled streptavidin.
- Reporter molecules may directly or indirectly generate detectable, and preferably measurable, signals.
- the linkage of reporter molecules may be directly or indirectly, covalently, e.g. via a peptide bond or non-covalently . Linkage via a peptide bond may be as a result of recombinant expression of a gene fusion encoding peptide or polypeptide and reporter molecule.
- Suitable fluorochromes include fluorescein, rhodamine, phycoerythrin and Texas Red.
- Suitable chromogenic dyes include diaminobenzidine .
- Other reporters include macromolecular colloidal particles or particulate material such as latex beads that are coloured, magnetic or paramagnetic, and biologically or chemically active agents that can directly or indirectly cause detectable signals to be visually observed, electronically detected or otherwise recorded. These molecules may be enzymes which catalyse reactions that develop or change colours or cause changes in electrical properties, for example.
- They may be molecularly excitable, such that electronic transitions between energy states result in characteristic spectral absorptions or emissions. They may include chemical entities used in conjunction with biosensors. Biotin/avidin or biotin/streptavidin and alkaline phosphatase detection systems may be employed.
- the mode of determining binding is not a feature of the present invention and those skilled in the art are able to choose a suitable mode according to their preference and general knowledge .
- Methods may be performed in vi tro on samples of cells and/or tissues removed from the body, or in vivo.
- Antibodies which are specific for a target of interest may be obtained using techniques which are standard in the art. Methods of producing antibodies include immunizing a mammal (e.g. mouse, rat, rabbit, horse, goat, sheep or monkey) with the protein or a fragment thereof, or a cell or virus which expresses the protein or fragment. Immunization with DNA encoding a target polypeptide is also possible (see for example Wolff, et al . Science 247: 1465-1468 (1990); Tang, et al . Nature 356: 152-154 (1992); Ulmer J B, et al .
- Antibodies may be obtained from immunised animals using any of a variety of techniques known in the art, and screened, preferably using binding of antibody to antigen of interest. For instance, Western blotting techniques or immunoprecipitation may be used (Armitage et al , 1992, Nature 357: 80-82) .
- Monoclonal antibodies can be subjected to the techniques of recombinant DNA technology to produce other antibodies or chimeric molecules which retain the specificity of the original antibody. Such techniques may involve introducing DNA encoding the immunoglobulin variable region, or the complementarity determining regions (CDRs) , of an antibody to the constant regions, or constant regions plus framework regions, of a different immunoglobulin. See, for instance,
- a hybridoma producing a monoclonal antibody may be subject to genetic mutation or other changes, which may or may not alter the binding specificity of antibodies produced.
- an antibody specific for a protein may be obtained from a recombinantly produced library of expressed immunoglobulin variable domains, e.g. using lambda bacteriophage or filamentous bacteriophage which display functional immunoglobulin binding domains on their surfaces; for instance see WO92/01047.
- the library may be naive, that is constructed from sequences obtained from an organism which has not been immunised with the target, or may be one constructed using sequences obtained from an organism which has been exposed to the antigen of interest (or a fragment thereof) .
- Antibodies may be modified in a number of ways. Indeed the term “antibody” should be construed as covering any specific binding substance having an binding domain with the required specificity. Thus this covers antibody fragments, derivatives, functional equivalents and homologues of antibodies, including any polypeptide comprising an immunoglobulin binding domain, whether natural or synthetic. Chimaeric molecules comprising an immunoglobulin binding domain, or equivalent, fused to another polypeptide are therefore included. Cloning and expression of chimaeric antibodies are described in EP-A-0120694 and EP-A- 0125023.
- Example binding fragments are (i) the Fab fragment consisting of VL, VH, CL and CHI domains; (ii) the Fd fragment consisting of the VH and CHI domains; (iii) the Fv fragment consisting of the VL and VH domains of a single antibody; (iv) the dAb fragment (Ward, E.S. et al .
- Peptides according to the invention may be used to identify receptor-specific antibodies, for instance in bacteriophages libraries (which may conveniently be in a scFv format) . This may be by displacment or other means of selection using purified receptor preparations, e.g. of o ⁇ 2 ⁇ l , or of the I- domain of the ⁇ l subunit of al ⁇ l , the I-domain of the ⁇ 2 subunit of CY2/31, or from cells expressing collagen receptors such as platelets or HT1080 cells, expressing ⁇ 2/3l, or from other cells such as megakaryocytes or platelets which express GpVI . In this way, antibodies specific for such collagen receptors may be identified.
- peptides may have similar properties and applications as peptides in accordance with the present invention.
- the peptides provide a route to the production of another set of materials (antibodies - e.g. scFvs) which may offer certain advantages, such as protection from proteolysis, when used therapeutically, compared with peptides of the invention. 6. Locating domains within collagens which interact with other collagen receptor molecules, e.g. CD36 (GpIV) . These interactions may present therapeutic targets themselves.
- Figure 1 shows the melting curve of peptide 6, plotting change in optical rotation (°) against temperature (°C).
- Figure 2 illustrates the binding of type I collagen and various 1(1) CB3 peptides (Peptides 1 to 4) to cel/32 integrin, the chart showing A 450 at various concentrations of substrate ( ⁇ g/ml) .
- Squares represent type 1 collagen, diamonds peptide 1, circles peptide 2, triangles peptide 3, crosses peptide 4.
- Figure 3 illustrates the binding of type I collagen and various ⁇ l(I) CB3 peptides (Peptides 5 to 7) to eel?2 integrin, the chart showing A 450 at various concentrations of substrate ( ⁇ g/ml).
- Squares represent type 1 collagen, diamonds peptide 5, circles peptide 6, triangles peptide 7.
- Figure 4 shows binding of collagen, Peptide 5/6 and Peptide 5/6GEA and 5/6GAR to cl/32 integrin in the absence and presence of Mg 2+ the chart showing A 450 .
- Figure 5 shows binding of collagen and Peptides Des-GVE, and Des-GPO to a.2 I-domain in the absence and presence of EDTA, and the inhibition of binding by the anti-ee2 antibody, 6F1, the chart showing A 450 at various concentrations of substrate ( ⁇ g/ml) .
- Figure 6 shows, as for Figure 5, binding of collagen and Peptides Des-GPA and Des-GFO to ce2 I-domain in the absence and presence of EDTA, and in the presence of 6F1, the chart showing
- Figure 7 shows binding of collagen and Peptides DesGVE and
- Figure 8 shows the binding of Peptides Des-GVE and GFOGDR to the eel I-domain, and inhibition of binding by an anti-eel antibody, AB, the chart showing A 450 .
- Figure 9 shows binding of collagen and Peptides Des-GVE- GPP, GFOGEK and MADE42 to integrin ce2 I-domain, in the presence and absence of Mg 2+ and the anti-ce2, 5E8, the chart showing A 450 .
- Figure 10 shows the ability of the peptide Des-GVE-GPP to inhibit platelet adhesion to collagens type I and type IV, the chart showing A 405 .
- Squares represent collagen type 1, diamonds collagen type IV.
- Figure 11 shows the ability of the peptide Des-GVE-GPP to inhibit binding of eel and ce2 I -domains to type I collagen, the chart showing A 450 - Squares represent eel I-domain, diamonds ce2
- Figure 12 shows the ability of the peptide Des-GVE-GPP to inhibit binding of ce2 I-domain to type I collagen, whereas
- DesGVE-GAP is inactive, the chart showing A 450 ' Squares represent Des-GVE-GPP, diamonds Des-GVE-GAP.
- Figure 13 shows the adhesion of platelets to the peptides CRP, GPP10,AcGPO2, AcGP04 and to collagen, and the effect of the presence of Mg 2+ or other divalent cations, the chart showing
- Figure 14 shows the adhesion of platelets to the peptides AcGP04 , CRP, and to collagen, and the effect of the presence of Mg 2+ , the anti-ce2, 6F1, or GpVI -specific Fab fragments, the chart showing A 405 .
- Figure 15 shows binding of collagen and Peptides Des-E-GPP, 56Hyp and GPP- 56 to integrin ce2 I-domain in the presence and absence of Mg 2+ , the chart showing A 450 .
- Peptide fragments of cel(I)CB3 were synthesized, as a series of overlapping peptides, incorporating them within GPO or GPP motifs as above, but, with one exception, without the use of C- terminal covalent crosslinking using hexanoic acid as outlined above.
- certain modifications of sequence have been performed, substituting A for E as shown.
- the peptides have been found to have a melting temperature sufficiently high to use for experimental purposes.
- alignment of constituent chains was guaranteed by synthesizing them on a template comprising the lysyl-lysyl aminohexanoate structure, thought to be needed for peptides with a low GPO content.
- alignment may be self-determining, representing the minimum free energy state of the associated peptides, and peptides may associate properly without hexanoic acid cross-linking.
- ce2/3l recognition sequence embraced by these peptides identified as being contained by the collagen-derived sequence from the overlap region of peptides 5 and 6, re-synthesised as Table 1 peptide 5/6, was also synthesised within GPP N-terminal and C-terminal sequences, as an alternative means of stabilising the triple helix.
- This peptide lacking GPO sequences, does not react with GpVI and is thus specific for ce2/3l.
- Platelet adhesion was measured in 35mm or other petri dishes (for which Falcon 1008 are suitable) using either a colorimetric method for cell adhesion (see Knight et al 1999) or 51 Cr-labelled gel-filtered human platelets as described (Zijenah and Barnes, 1990) .
- platelets were preincubated with antibody for 15 min.
- Statistical significance of the effect of mAbs was determined by one-way analysis of variance ("ANOVA"), using readily available computer statistical software (Instat, produced by GraphPad, San Diego, CA, USA) , either within experiments or using the mean values from at least three separate experiments.
- Platelet aggregation was measured turbidimetrically using human citrated platelet-rich plasma as previously (Morton et al . , 1995) .
- Alternative methods of measuring aggregation are possible, e.g. electronic particle counting or impedance measurement (McNicol, 1995).
- HT 1080 cells obtainable for example from the European Collection of Animal Cell Cultures, Porton Down, Wiltshire, UK, were maintained in Eagle's MEM containing 15% FBS , 2mM glutamine, penicillin (100 I.U./ml), streptomycin (100 ⁇ g/ml) and amphotericin (2.5 ng/ml), or other growth medium as appropriate. Cells were harvested with trypsin/EDTA, suspended in Eagle's MEM or other buffer containing 20% FBS, washed four times with Dulbecco's PBS (Ca 2+ and Mg 2+ free) and finally suspended in adhesion buffer (TBS) containing ImM Mg 2+ .
- TBS adhesion buffer
- Immulon 2 or other suitable multi-well plates were coated with collagen or peptide, normally at 10 ⁇ g/ml, for lh at 20 °C.
- Cell suspension (0.1ml, 3xl0 4 cells) was added to each well and adhesion measured after 90 min at 20 °C or 37 °C, as required. Adhesion was determined using a Coulter Counter (model ZF) to count unattached cells.
- the colorimetric method used for platelets (Bellavite at al . , 1994 Anal. Biochem. 216: 444-4500 was readily adapted to provide a suitable alternative for HT1080 and other cell adhesion assays. Cells were preincubated with antibody, when testing for inhibition, for 15 min. The significance of any inhibition of adhesion by mAbs was tested using the same statistical analysis as for platelets.
- Integrin ce2/3l was purified from solubilized membranes of human platelets by affinity chromatography on collagen-Sepharose as described in detail by Messent et al . (Kern et al . , 1993) . The purity was established by polyacrylamide gel electrophoresis, immunoprecipitation and Western blotting. Protein concentration was determined with BCA reagent (Pierce) or other suitable methodology and the purified integrin biotinylated using a biotinylation kit (available for example from Amersham) according to the manufacturer's instructions. Integrin ce23l binding assay
- the assay procedure was essentially as described by Tuckwell et al . , 1995. Briefly, wells of 96-well ELISA plates (Nunc Maxisorp) were coated with 100 ⁇ l of a solution of collagen or peptide, 1-10 ⁇ g/ml in O.OlM-acetic acid for 2h at room temperature. Wells were then blocked for lh with 100 ⁇ l of TBS (150mM NaCl in 50mM tris-HCl, pH 7.4) containing BSA (Sigma, grade A4503) at 50mg/ml and washed three times with 200 ⁇ l of TBS containing BSA (Sigma, grade A7638) at lmg/ml (washing buffer) .
- TBS 150mM NaCl in 50mM tris-HCl, pH 7.4
- BSA Sigma, grade A4503
- adhesion buffer 100 ⁇ l of adhesion buffer (washing buffer plus either 2mM-MgCl2 and lmM-MnCl2 or lOmM-EDTA [disodium salt] , as required) containing biotinylated integrin at 0.5 ⁇ g/ml, was applied to each well and incubated for 2h at room temperature. Wells were then washed as above and incubated for 30min with 100 ⁇ l of streptavidin-HRP (Amersham Life Sciences) diluted 1:1500 with washing buffer. The wells were again washed three times and bound integrin detected using a TMB-peroxidase substrate system (KPL, Gaithersburg, Maryland, USA) according to the manufacturer's instructions.
- TMB-peroxidase substrate system KPL, Gaithersburg, Maryland, USA
- Optical density was recorded using a Maxline Emax plate reader (Molecular Devices) or other suitable instrument. Assays were undertaken in triplicate and values were corrected for a background reading obtained by coating wells with O.OlM-acetic acid in the absence of peptide or collagen substrate.
- Binding was assayed essentially as described by Tuckwell et al . , 1995. Briefly, Nunc Maxisorp multiwell plates were coated for lh at room temperature with collagen or peptides and blocked with BSA, as described above. After blocking, wells were washed three times with TBS containing lmM-MgCl 2 and BSA (lmg/ml) .
- Any suitable method of synthesising peptides may be used. The following was found to be suitable.
- Peptides were synthesized as C-terminal amides on TentaGel R RAM resin in a PerSeptive Biosystems 9050 Plus PepSynthesiser by Fmoc/t-Bu chemistry. Side chain protecting groups were as follows: Arg(Pbf), Asn(Trt), Asp(Ot-Bu), Cys(Trt), Gln(Trt), Glu(Ot-Bu), Hyp(t-Bu) and Lys (Boc) . In general, Fmoc-amino acids (4 eq.) were activated with HATU (4 eq.) in the presence of diisopropylethylamine (8 eq.) (Carpino et al .
- Peptides were released from the resin by treatment with a mixture of trifluoroacetic acid, thioanisole, ethanediol and triisopropylsilane (90:5:2.5:2.5, by vol.) for 6 hours at room temperature.
- Crude peptides were purified by reverse phase HPLC on a column of Vydac 219TP101522 using a linear gradient of 5 to 45% acetonitrile in water containing 0.1% trifluoroacetic acid.
- Fractions containing homogeneous product were identified by analytical HPLC on a column of Vydac 219TP54, pooled and freeze- dried. The identity of the purified peptides was confirmed by mass spectrometry .
- Peptides were crosslinked with 3- (2-pyridyldithio) - propionic acid N-hydroxysuccinimide ester as before (Morton et al . , 1995) .
- peptides have a conformationally constrained structure for interaction with their receptors. This was verified for the peptides of triple-helical conformation, by optical rotation using a polarimeter (Morton e al . , 1995) .
- HT1080 cells express ce2/3l integrin and so were used in a further test of adhesion mediated by this integrin.
- the cells showed no significant adhesion to Peptides 2, 3, 4 and 7, but good adhesion to Peptides 5, 6 and 5/6 - as good as to collagen, i.e. about 80% at room temperature at 90 minutes. Adhesion to Peptide 1 was about 60%.
- Adhesion to collagen and Peptides 1, 5, 6 and 5/6 was strongly inhibited by anti-ce2 integrin, 6F1 (Coller et al . , 1989, Blood, 74:182-192) inhibition varying between experiments from 65-90%. Any residual adhesion in the presence of 6F1 occurred in the total absence of cell spreading .
- the Peptide 5/6GAR was found to lack capacity to bind o ⁇ 2 ⁇ l , indicating the importance of Glu residues for binding of 5/6 (and by inference collagen) to a2 ⁇ l , and similarly, the Arg residue could not be substituted by Ala.
- Figure 8 shows that this same sequence, GFOGER, in Des- GVE, supports binding of the eel I-domain, so that the sequence is also recognised by the integrin cel/3l .
- GFOGDR showed no ability to support eel binding.
- Figure 9 shows that substitution of R by K, in the peptide GFOGEK, does not support ce2 binding. Hence two conservative substitutions may destroy the ability of the sequence to recognise ce2/3l. This was verified using purified ce2/3l binding and intact platelet binding.
- the peptide MADE42 comprises tandem GFOGER motifs separated by intervening GPP triplets, and with GPP triplets at the N and C-termini of the peptide.
- This peptide showed adhesion of ce2 I-domain as good as type I collagen, although rather lower than Des-GVE-GPP which contains a single copy of the GFOGER motif. This peptide will provide a tool to study crosslinking of receptors such as ce2/31 and cel/3l.
- Figure 12 shows the importance of peptide conformation in this respect: a version of the sequence GFOGER was synthesised in GAP polymeric sequences, which do not support triple helical structure, i.e. no melting curve as in Figure 1 could be obtained.
- This peptide, Des-GVE-GAP did not inhibit ce2 I-domain binding.
- Figure 13 shows firstly, that GPP polymers do not support platelet adhesion, although CRP, the GPO polymer does so.
- Two variant peptides were synthesised and tested, AcGP02 and AcGP04. These are essentially GPP polymers containing tandem and quadruplet GPO sequences, as shown in Table 1.
- Figure 14 provides proof, obtained using the anti-GpVI Fab fragment, that adhesion of platelets to AcGP04 and to CRP, though not collagen, is dependent upon GpVI, but is independent of ce2/3l, since the anti-ce2 antibody, 6F1 had little effect on platelet adhesion.
- this provides proof, in conjunction with Figure 13, that neither the GPO not GPP motifs recognise ce2/3l.
- Figure 15 indicates interchangeability of hydroxyproline (O or P*) and proline (P) residues in recognition by a2 ⁇ l .
- Peptides containing variants of the 15-amino acid sequence from the overlap region of Peptides 5 and 6 were used as substrates for adhesion of ce2 I-domain.
- Peptide GPP- 56 contains two proline residues in place of hydroxyproline, and supports good adhesion.
- Peptide 56 -Hyp contains proline only in the first triplet of the sequence, and supports rather better adhesion.
- Substitution of P for O with GFOGER permits retention of ce2/3l -binding.
- Substituting alanine (A) for both glutamates (E) as well as P for 0 results in loss of adhesive capacity for ce2/3l.
- GPC GPC 3 GFOGPKGAAGEOGKAGERGVOGPOGAVGPA (GPO) 3 GPC
- GPC 3 GPOGAVGPAGKDGEAGAQGPOGPAGPAGER (GPO) 3 GPC
- GPC GPC
- GPO GPC
- GPC GPC
- GPC GPC
- GPC GDLGAOGPSGARGERGFOGERGVEGPOGPA (GPO) 3 GPC
- GPC GPO
- GPO GFOGERGVEGPOGPAGPRGANGAOGNDGAK
- GPC GPC 3 GANGAOGNDGAKGDAGAOGAOGSQGAOGLQ (GPO) 3 GPC
- GPC GPO
- GFOGARGVAGPOGPA GPO
- GPC GPO
- GFOGARGVEGPOGPA GPO
- GPC GPO 3 GFOGERGVEGPO (GPO) 3 GPCG
- GPC GPO
- GPO 3 GERGVEGPOGPA
- GPO 3 GPCG
- GPC GPO
- GFOGERGVE GPO
- GPC GPO
- GFOGER GPO
- GPC GPC 5 GFPGERGVEGPPGPA (GPP) 5 GPC
- GPC GPC 5 GFPGARGVAGPPGPA (GPP) 5 GPC
- GPC GPC 3 GFOGER (GPP) 4 GFOGER (GPP) 3 GPC
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002325017A CA2325017A1 (en) | 1998-03-30 | 1999-03-30 | Collagen peptides and uses thereof |
JP2000541183A JP2002509708A (en) | 1998-03-30 | 1999-03-30 | Collagen peptide and use thereof |
AU31605/99A AU3160599A (en) | 1998-03-30 | 1999-03-30 | Collagen peptides and uses thereof |
EP99913492A EP1068313A2 (en) | 1998-03-30 | 1999-03-30 | Collagen peptides and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9806806.7A GB9806806D0 (en) | 1998-03-30 | 1998-03-30 | Peptides and uses thereof |
GB9806806.7 | 1998-03-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999050281A2 true WO1999050281A2 (en) | 1999-10-07 |
WO1999050281A3 WO1999050281A3 (en) | 1999-12-02 |
Family
ID=10829553
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1999/000992 WO1999050281A2 (en) | 1998-03-30 | 1999-03-30 | Collagen peptides and uses thereof |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1068313A2 (en) |
JP (1) | JP2002509708A (en) |
AU (1) | AU3160599A (en) |
CA (1) | CA2325017A1 (en) |
GB (1) | GB9806806D0 (en) |
WO (1) | WO1999050281A2 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001073444A2 (en) * | 2000-03-28 | 2001-10-04 | Cambridge University Technical Services Limited | Receptor/peptide crystal structure for identification of inhibitors |
WO2003097875A1 (en) * | 2002-05-22 | 2003-11-27 | Willem Ouwehand | Diagnosis of abnormal blood conditions based on polymorphisms in the glycoprotein vi gene |
WO2005012348A2 (en) * | 2003-08-01 | 2005-02-10 | Adherex Technologies Inc. | Cyclic cadherin analogues comprising the sequence hav for modulating the migration of vascular smooth muscle cells |
WO2007017671A1 (en) * | 2005-08-09 | 2007-02-15 | Cambridge Enterprise Limited | Collagen peptides, methods and uses |
WO2007052067A2 (en) * | 2005-11-07 | 2007-05-10 | Cambridge Enterprise Limited | Von willebrand factor (vwf) binding peptides |
EP1889062A2 (en) * | 2005-06-03 | 2008-02-20 | The Texas A & M University System | Specific binding sites in collagen for integrins and use thereof |
US7387779B2 (en) | 1998-06-17 | 2008-06-17 | Beth Israel Deaconess Medical Center | Anti-angiogenic proteins and fragments and methods of use thereof |
EP1965813A2 (en) * | 2005-11-16 | 2008-09-10 | The University of Tennessee Research Foundation | Methods of treating fibrosing diseases by induction of immune tolerance |
WO2009018126A2 (en) * | 2007-08-01 | 2009-02-05 | Ethicon, Inc. | Collagen-related peptides and uses thereof |
US7514543B2 (en) | 2002-06-07 | 2009-04-07 | Trigen Gmbh | Polynucleotides encoding immunoadhesins comprising a glycoprotein VI domain |
US7531178B2 (en) | 2002-06-07 | 2009-05-12 | Trigen Gmbh | Immunoadhesin comprising a glycoprotein VI domain |
US8119135B2 (en) | 2002-06-07 | 2012-02-21 | Helmhotz Zentrum Munchen, Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) | Antibodies which bind to epitopes of glycoprotein VI |
US20120149114A1 (en) * | 2010-12-08 | 2012-06-14 | Becton, Dickinson And Company | Methods For Cell Culture Using A Synthetic, Defined Collagen Mimetic Surface |
WO2018022553A1 (en) | 2016-07-25 | 2018-02-01 | Cerapedics, Inc. | Peptide-coated calcium phosphate particles |
CN114931665A (en) * | 2021-12-14 | 2022-08-23 | 广州医科大学 | Application of hexa-type collagen alpha 2 subunit in nerve repair product |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014008454A2 (en) * | 2012-07-06 | 2014-01-09 | Jnc Corporation | Aspirin response and reactivity test and aspirin compliance test using synthetic collagen |
JP6183459B2 (en) * | 2012-08-06 | 2017-08-23 | Jnc株式会社 | Dual antiplatelet / aspirin response and reactivity studies using synthetic collagen |
US20150198620A1 (en) * | 2012-08-09 | 2015-07-16 | Jnc Corporation | Anti-platelet response and reactivity test using synthetic collagen |
-
1998
- 1998-03-30 GB GBGB9806806.7A patent/GB9806806D0/en not_active Ceased
-
1999
- 1999-03-30 AU AU31605/99A patent/AU3160599A/en not_active Abandoned
- 1999-03-30 CA CA002325017A patent/CA2325017A1/en not_active Abandoned
- 1999-03-30 WO PCT/GB1999/000992 patent/WO1999050281A2/en not_active Application Discontinuation
- 1999-03-30 JP JP2000541183A patent/JP2002509708A/en active Pending
- 1999-03-30 EP EP99913492A patent/EP1068313A2/en not_active Withdrawn
Non-Patent Citations (4)
Title |
---|
B. GRAB ET AL.: "Promotion of Fibroblast Adhesion by Triple-helical Peptide Models of Type I Collagen-derived Sequences" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 21, 24 May 1996 (1996-05-24), pages 12234-12240, XP002118049 BALTIMORE, MD US * |
C.G. KNIGHT ET AL.: "Identification in Collage Type I of an Integrin alpha2beta1-binding Site Containing an Essential GER Sequence" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 50, 11 December 1998 (1998-12-11), pages 33287-33294, XP002118048 BALTIMORE, MD US * |
L.F. MORTON ET AL.: "The Platelet Reactivity of Synthetic Peptides based on the Collagen Fragment alpha1(III)CB4" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 17, 25 April 1997 (1997-04-25), pages 11044-11048, XP002118051 BALTIMORE, MD US * |
T.M. CHIANG AND A.H. KANG: "A Synthetic Peptide Derived from the Sequence of a Type I Collagen Receptor Inhibits Type I Collagen-mediated Platelet Aggregation" JOURNAL OF CLINICAL INVESTIGATION, vol. 100, no. 8, October 1997 (1997-10), pages 2079-2084, XP002118050 * |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7122623B2 (en) | 1996-07-12 | 2006-10-17 | Adherex Technologies, Inc. | Compounds and methods for modulating cell adhesion |
US7387779B2 (en) | 1998-06-17 | 2008-06-17 | Beth Israel Deaconess Medical Center | Anti-angiogenic proteins and fragments and methods of use thereof |
WO2001073444A3 (en) * | 2000-03-28 | 2002-05-16 | Univ Cambridge Tech | Receptor/peptide crystal structure for identification of inhibitors |
WO2001073444A2 (en) * | 2000-03-28 | 2001-10-04 | Cambridge University Technical Services Limited | Receptor/peptide crystal structure for identification of inhibitors |
WO2003097875A1 (en) * | 2002-05-22 | 2003-11-27 | Willem Ouwehand | Diagnosis of abnormal blood conditions based on polymorphisms in the glycoprotein vi gene |
US7855050B2 (en) | 2002-05-22 | 2010-12-21 | Willem Ouwehand | Diagnosis of abnormal blood conditions based on polymorphisms in the glycoprotein VI gene |
US8119135B2 (en) | 2002-06-07 | 2012-02-21 | Helmhotz Zentrum Munchen, Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) | Antibodies which bind to epitopes of glycoprotein VI |
US7514543B2 (en) | 2002-06-07 | 2009-04-07 | Trigen Gmbh | Polynucleotides encoding immunoadhesins comprising a glycoprotein VI domain |
US7531178B2 (en) | 2002-06-07 | 2009-05-12 | Trigen Gmbh | Immunoadhesin comprising a glycoprotein VI domain |
WO2005012348A2 (en) * | 2003-08-01 | 2005-02-10 | Adherex Technologies Inc. | Cyclic cadherin analogues comprising the sequence hav for modulating the migration of vascular smooth muscle cells |
WO2005012348A3 (en) * | 2003-08-01 | 2005-04-28 | Adherex Technologies Inc | Cyclic cadherin analogues comprising the sequence hav for modulating the migration of vascular smooth muscle cells |
US7514531B2 (en) * | 2005-06-03 | 2009-04-07 | The Texas A&M University System | Specific binding sites in collagen for integrins and use thereof |
US10358464B2 (en) | 2005-06-03 | 2019-07-23 | The Texas A&M University System | Specific binding sites in collagen for integrins and use thereof |
WO2006133107A3 (en) * | 2005-06-03 | 2009-04-30 | Texas A & M Univ Sys | Specific binding sites in collagen for integrins and use thereof |
EP1889062A4 (en) * | 2005-06-03 | 2009-12-23 | Texas A & M Univ Sys | Specific binding sites in collagen for integrins and use thereof |
EP1889062A2 (en) * | 2005-06-03 | 2008-02-20 | The Texas A & M University System | Specific binding sites in collagen for integrins and use thereof |
US20130150300A1 (en) * | 2005-06-03 | 2013-06-13 | The Texas A&M University System | Specific binding sites in collagen for integrins and use thereof |
US8252553B2 (en) * | 2005-06-03 | 2012-08-28 | The Texas A&M University System | Specific binding sites in collagen for integrins and use thereof |
WO2007017671A1 (en) * | 2005-08-09 | 2007-02-15 | Cambridge Enterprise Limited | Collagen peptides, methods and uses |
WO2007052067A2 (en) * | 2005-11-07 | 2007-05-10 | Cambridge Enterprise Limited | Von willebrand factor (vwf) binding peptides |
WO2007052067A3 (en) * | 2005-11-07 | 2007-08-02 | Cambridge Entpr Ltd | Von willebrand factor (vwf) binding peptides |
EP1965813A2 (en) * | 2005-11-16 | 2008-09-10 | The University of Tennessee Research Foundation | Methods of treating fibrosing diseases by induction of immune tolerance |
EP1965813A4 (en) * | 2005-11-16 | 2012-07-04 | Univ Tennessee Res Foundation | Methods of treating fibrosing diseases by induction of immune tolerance |
WO2009018126A2 (en) * | 2007-08-01 | 2009-02-05 | Ethicon, Inc. | Collagen-related peptides and uses thereof |
US8076294B2 (en) | 2007-08-01 | 2011-12-13 | Advanced Technologies And Regenerative Medicine, Llc. | Collagen-related peptides and uses thereof |
WO2009018126A3 (en) * | 2007-08-01 | 2009-03-19 | Ethicon Inc | Collagen-related peptides and uses thereof |
US20120149114A1 (en) * | 2010-12-08 | 2012-06-14 | Becton, Dickinson And Company | Methods For Cell Culture Using A Synthetic, Defined Collagen Mimetic Surface |
WO2018022553A1 (en) | 2016-07-25 | 2018-02-01 | Cerapedics, Inc. | Peptide-coated calcium phosphate particles |
CN114931665A (en) * | 2021-12-14 | 2022-08-23 | 广州医科大学 | Application of hexa-type collagen alpha 2 subunit in nerve repair product |
Also Published As
Publication number | Publication date |
---|---|
WO1999050281A3 (en) | 1999-12-02 |
CA2325017A1 (en) | 1999-10-07 |
AU3160599A (en) | 1999-10-18 |
JP2002509708A (en) | 2002-04-02 |
EP1068313A2 (en) | 2001-01-17 |
GB9806806D0 (en) | 1998-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5817750A (en) | Structural mimics of RGD-binding sites | |
EP1068313A2 (en) | Collagen peptides and uses thereof | |
Pfaff et al. | Integrin and Arg-Gly-Asp dependence of cell adhesion to the native and unfolded triple helix of collagen type VI | |
Cheresh et al. | Recognition of distinct adhesive sites on fibrinogen by related integrins on platelets and endothelial cells | |
AU682561B2 (en) | Novel integrin-binding peptides | |
US5190920A (en) | Method for using synthetic analogs of thrombospondin for inhibiting metastasis activity | |
US7514531B2 (en) | Specific binding sites in collagen for integrins and use thereof | |
US8642728B2 (en) | Modulation of the activity and differentiation of cells expressing the osteoclast-associated receptor | |
BRPI0707920A2 (en) | monomeric peptide, multimeric peptide comprising it, its use, dimeric peptide, fusion and pharmaceutical composition comprising the same, as well as in vitro fcrn detection methods, sintering of a peptide dimer and for fcrn purification | |
JPH05502228A (en) | Peptides and antibodies that inhibit integrin-ligand binding | |
WO2007017671A1 (en) | Collagen peptides, methods and uses | |
WO2007052067A2 (en) | Von willebrand factor (vwf) binding peptides | |
US20210115106A1 (en) | Modified t cell receptors | |
EP0514721A1 (en) | Peptides having thrombospondin-like activity and their therapeutic use | |
WO1994018345A1 (en) | Receptor-binding antiproliferative peptides | |
AU755574B2 (en) | Synthetic peptide immunogens and antibodies thereto | |
US5648461A (en) | Synthetic analogs of thrombospondin and therapeutic use thereof | |
AU2005252297A1 (en) | Heparin binding peptide | |
KR101782623B1 (en) | Antigen Derived from Extracellular Domain of Multi-transmembrane Protein and Uses Thereof | |
Ito et al. | Screening of peptides that inhibit bacterial binding to fibronectin using combinatorial peptide libraries |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase in: |
Ref country code: CA Ref document number: 2325017 Kind code of ref document: A Format of ref document f/p: F Ref document number: 2325017 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 31605/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999913492 Country of ref document: EP |
|
NENP | Non-entry into the national phase in: |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09647396 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1999913492 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999913492 Country of ref document: EP |